Abbott Laboratories agreed to consummate its troubled acquisition of Alere Inc. in a deal that values the medical test makerâs equity at $5.3 billion, shaving $500 million from the original price and ending months of legal maneuvering that appeared headed for a Delaware court.
Alere shareholders will get $51 a share in cash, according to a statement Friday. While the new price is an 8.9 percent cut from the deal announced in February 2016, itâs a 21 percent jump from the companyâs closing price ...
Share this post
← Back to Utah